Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

Cassava Sciences stock collapsed after an Alzheimer’s drug the company was testing failed to significantly help participants ...

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Research analysts at HC Wainwright decreased their FY2024 earnings estimates for shares of Cassava Sciences in a research report issued on Tuesday, November 26th. HC Wainwright analyst V. Bernardino ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences Inc’s profitability metrics reveal financial health. The company currently boasts an operating margin of 0.00% with a gross margin of -82.27%. The profit margin, also known as the ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

H.C. Wainwright analyst Vernon Bernardino downgraded Cassava Sciences (SAVA) to Neutral from Buy without a price target after the company ...